Related Experiment Video

Updated: May 20, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives

Andrew X Zhu1

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. azhu@partners.org

Seminars in Oncology
|August 1, 2012
PubMed

Insights

New systemic therapies are crucial for advanced hepatocellular carcinoma (HCC). This review summarizes targeted agents beyond sorafenib, offering hope for improved patient survival in HCC treatment.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Oncology
  • Molecular Targeted Therapy

Background:

  • Advanced hepatocellular carcinoma (HCC) survival remains poor despite sorafenib.
  • Sorafenib offers modest benefits, necessitating novel systemic therapies.
  • Significant research is underway to develop new molecularly targeted agents for HCC.

Purpose of the Study:

  • To review molecularly targeted agents beyond sorafenib for advanced HCC.
  • To summarize the current status of investigational therapies in HCC.
  • To discuss future perspectives for advanced HCC treatment.

Main Methods:

  • Literature review of clinical trials and research on targeted agents in HCC.
  • Analysis of agents targeting pathways like EGFR, mTOR, and c-Met.
  • Examination of combination strategies involving targeted agents and chemotherapy.

Main Results:

  • Several molecularly targeted agents are in clinical trials for advanced HCC.
  • Anti-angiogenic therapies, EGFR, mTOR, and c-Met inhibitors show promise.
  • Combination therapies are being explored to enhance efficacy.

Conclusions:

  • Development of novel systemic therapies is critical for improving advanced HCC outcomes.
  • Targeted agents beyond sorafenib represent a promising frontier in HCC treatment.
  • Continued research and clinical trials are essential for advancing HCC care.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...